The emergence of dual-action receptor agonists in the management of type 2 diabetes and obesity has sparked considerable interest, particularly regarding retatrutide and tirzepatide. While both medications target both https://berthaufgq433494.educationalimpactblog.com/60236989/retatrutide-vs-tirzepatide-a-comparative-analysis